Sionna Therapeutics, Inc. (NASDAQ:SION) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $50.5714.

A number of research analysts recently issued reports on the company. Citizens Jmp started coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Finally, UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 33,356 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the transaction, the director directly owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. This trade represents a 0.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter A. Thompson sold 33,356 shares of Sionna Therapeutics stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the sale, the director directly owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. This trade represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 378,618 shares of company stock worth $15,731,751 in the last quarter. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Several large investors have recently made changes to their positions in SION. Viking Global Investors LP boosted its holdings in Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after acquiring an additional 242,427 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Sionna Therapeutics by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after purchasing an additional 51,589 shares during the last quarter. Vanguard Group Inc. lifted its position in Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the period. Jennison Associates LLC lifted its position in Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares during the period. Finally, Braidwell LP bought a new position in shares of Sionna Therapeutics in the 2nd quarter valued at about $18,770,000.

Sionna Therapeutics Price Performance

NASDAQ SION opened at $36.39 on Friday. The stock’s 50 day simple moving average is $38.18 and its 200 day simple moving average is $36.35. Sionna Therapeutics has a one year low of $7.26 and a one year high of $45.00. The firm has a market cap of $1.64 billion and a PE ratio of -18.66.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.